The differential diagnosis of acute inflammatory transverse myelitis (ATM) is broad. Therefore, physicians must be aware of the many potential etiologies for acute myelopathy, and should pursue an ordered, efficient, and cost-effective approach to the diagnosis based on the patient's clinical history, examination, and magnetic resonance imaging (MRI) findings. Clinical, immunological, and radiological findings of noncompressive myelopathies are reviewed, as are how these findings can be used to distinguish between demyelinating, infectious, other inflammatory, vascular, neoplastic, and paraneoplastic etiologies. We also review predictors of further episodes of ATM in patients with demyelinating disorders. We discuss the diagnostic clues and pitfalls of the not uncommon clinical scenario of a presumed ''myelopathy with normal MRI.'' Finally, we suggest an algorithm for the diagnosis and management of acute myelopathies.
tory myelitis, is one of the causes of acute transverse myelopathy. The three main categories in the differential diagnosis of ATM are demyelination, including multiple sclerosis (MS), neuromyelitis optica (NMO), and idiopathic transverse myelitis; infections such as herpes zoster and herpes simplex virus; and other inflammatory disorders such as systemic lupus erythematosus (SLE) and neurosarcoidosis. However, whether the cause of the acute myelopathy is inflammatory or not is not selfevident; therefore, the clinical and diagnostic workup for ATM requires that other causes of acute myelopathies be excluded.
When faced with a patient with an acute myelopathy, excluding an acute compressive cause is of utmost priority. A magnetic resonance imaging (MRI) scan is invaluable in this regard. Having excluded a compressive cause and having found an intrinsic spinal cord lesion on MRI, a detailed history and an examination followed by focused investigations are needed. In the following sections, clinical presentations of myelopathies are discussed followed by diagnostic categories of acute myelopathy. Only the classical presentations of the diseases are covered here. The predictors of relapses in demyelinating myelopathies are included, followed by an algorithm on diagnosis and treatment. Although we have used available literature and guidelines throughout, there may be instances where our personal clinical practice and experience have influenced our opinions and approach.
CLINICAL PRESENTATION OF SPINAL CORD DISORDERS
Spinal cord disorders are conventionally classified as ''syndromes'' due to the typical signs and symptoms produced because of the location of the lesion and specific tract involvement. The Brown-Séquard hemicord syndrome is an example. Table 1 summarizes the clinical presentation of acute spinal cord disorders.
Myelopathies with selective tract involvement are characteristic of metabolic or degenerative myelopathies (which are usually chronic) rather than inflammatory or infectious disorders (e.g., corticospinal and posterior columns in B 12 deficiency, adrenomyeloneuropathy, and Friedreich's ataxia). However, paraneoplastic myelopathies, which are rare, often produce tract-specific involvement and should be considered when investigations to exclude a metabolic or degenerative myelopathy are negative in acute symmetric ''tractopathy.'' Occasionally, inflammatory demyelinating syndromes may present with a very selective tractopathy due to discrete lesions (e.g., the classical acute ''sensory useless hand syndrome'' with acute proprioceptive loss due to posterior column involvement in patients with MS).
NONCOMPRESSIVE CAUSES OF ACUTE MYELOPATHIES
The five groups of disorders that present as acute myelopathy are: demyelination, infections, other inflammatory disorders, vascular, and neoplastic and paraneoplastic. The first three are considered inflammatory disorders. Among these, demyelinating disorders are the most common. The initial task of the clinician is to determine which of these is most likely. In general, inflammatory disorders have an inflammatory cerebrospinal fluid (CSF) manifested by either pleocytosis, raised IgG index or both. Fig. 1 is an algorithm on the diagnosis and management of acute noncompressive myelopathies.
Demyelinating Disorders
Typically, the onset of neurological symptoms in myelitis due to demyelination occurs over days with sensory motor symptoms and bladder and bowel disturbances, although occasionally necrotizing demyelinating myelopathies, including NMO, may progress over hours. They usually occur in individuals who are otherwise in good health and may be preceded by a nonspecific viral illness. Table 2 provides the differential diagnoses of demyelinating myelopathies and their clinical-radiological features. 
MULTIPLE SCLEROSIS
In MS, lesions are usually small (< 2 vertebral segments in length) and peripheral, and therefore cause asymmetric symptoms and signs (Fig. 2 ). Lhermitte's sign (paresthesias spreading down the spine, often into the legs, on neck movement) is typical for a demyelinating lesion of the cervical posterior columns, but can be, although rarely, seen in other conditions that involve the same site. Other characteristic syndromes include isolated proprioceptive loss of an upper extremity (''sensory useless hand syndrome''), 1 Brown-Séquard syndrome, or, more commonly, incomplete versions thereof. Early in Figure 1 Diagnostic approach to acute myelopathy. MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; NMO, neuromyelitis optica; MS, multiple sclerosis; IgG, immunoglobulin G; SS-A, Sjö gren's syndrome antibody (anti-Ro). 
NEUROMYELITIS OPTICA
Neuromyelitis optica is most commonly a relapsing demyelinating condition of the central nervous system (CNS) affecting predominantly the optic nerves and spinal cord. Table 3 lists the recently revised criteria for NMO. Lesions are centrally located and necrotic leading to more symmetric symptoms and signs, greater disability than seen in MS, and less complete recovery. The lesions in the cord are typically long (> 3 vertebral segments) (Fig. 3) . A history of severe optic neuritis should raise suspicion of NMO. NMO is relatively more common in Asian and African individuals, although the majority of patients with this condition in western countries are white. A variety of autoimmune conditions including SLE, Sjögren's syndrome, and thyroid autoimmune disorders may coexist with NMO. NMO-IgG is a recently identified serum antibody that is highly specific (> 90%) and sensitive (> 70%) for NMO. 5 It is also present in NMO spectrum disorders, including limited forms of NMO such as relapsing optic neuritis and relapsing myelitis. When identified at the first attack, NMOIgG also predicts future episodes of myelitis or optic neuritis. In a prospective study, the risk of developing recurrent myelitis or new onset optic neuritis in patients with an isolated longitudinally extensive transverse myelitis was more than 50% among those who were NMO-IgG seropositive, compared with 0% in those who were NMO-IgG seronegative. 6 Brain MRI can be abnormal in NMO. Typically, lesions are periventricular, especially in regions of high concentration of aquaporin-4, the target antigen for the NMO-IgG. 7 
ACUTE DISSEMINATED ENCEPHALOMYELTIS
Acute disseminated encephalomyelitis (ADEM) is a monophasic disorder that affects the brain and occasionally the spinal cord. 8 Often there is a history of preceding viral or other infectious illness. The brain and spinal cord show demyelinating lesions that are generally of the same age, although gadolinium enhancement may not be seen in all, and, occasionally, not in any of the lesions. ADEM may evolve over the course of up to 3 months.
ADEM is more common in children, and is only reliably diagnosed in individuals who have concomitant encephalopathy. Follow-up of individuals with a clinical diagnosis of ADEM reveals that 25% of cases (Table 4) . However, the idiopathic nature is a diagnosis of exclusion. The bimodal peaks in onset ages are 10 to 19 years and 30 to 39 years. A preceding nonspecific fever, nausea, or muscle pain, possibly indicating a prior viral infection, is common, although one or more of these symptoms may also precede attacks of MS and NMO. The lesion length varies from less than one segment to the entire cord. Many of these large series of patients were reported before NMO-IgG was identified, and it is possible that many such patients may have an NMO spectrum disorder. The proportion of ''idiopathic'' inflammatory transverse myelitis is likely to decline with the increasing availability of newer autoimmune markers, imaging techniques, and microbiological tests capable of defining a specific etiology.
Assessment for Recurrence Risk in Demyelinating Myelopathies
After management of acute myelitis with steroids and/or plasma exchange, demyelinating myelopathies need to be evaluated for the risk of recurrence. The major decision point is whether a patient has complete or incomplete transverse myelitis (Fig. 1) . Complete transverse myelitis usually has more or less symmetrical findings and involvement of motor, sensory, and sphincter function. Incomplete transverse myelitis usually has asymmetric findings that may involve a limited number of tracts and does not typically result in loss of all motor, sensory, and sphincter function. In general, complete transverse myelitis is associated with a long spinal cord lesion exceeding three vertebral segments in length, often central within the cord, and an incomplete transverse myelitis is associated with a short spinal cord lesion, typically one to two segments in length and peripheral. However, there are exceptions to this general rule.
Patients with Complete Transverse Myelitis
Complete transverse myelitis patients, in general, are at low risk for future development of MS. However, they could have recurrences consistent with relapsing myelitis or NMO. Two autoimmune markers that may predict recurrence are anti-Sjögren's syndrome antibody (SS-A) and NMO-IgG. 18 NMO-IgG predicted each case of recurrence in a Mayo Clinic series, 6 Thirty-eight percent of patients with a first episode of transverse myelitis were seropositive for NMO-IgG in a recent Mayo Clinic series; more than 50% of those followed for 1 year had recurrent myelitis or optic neuritis, whereas none of the seronegative patients experienced recurrence. 6 We currently advise testing for NMO-IgG in patients who have experienced a first episode of longitudinally extensive transverse myelitis, and instituting immunosuppressive therapy in those positive for NMO-IgG. We believe that monophasic inflammatory demyelinating transverse myelitis in patients seropositive for NMO-IgG is a limited form of NMO with a high risk of relapse, or an NMO spectrum disorder, and should be managed accordingly.
Patients with Incomplete Transverse Myelitis
This group of patients is currently regarded as having a clinically isolated syndrome (CIS), which places them at risk for developing other symptoms that will lead to a definite diagnosis of MS. Cranial MRI is used to determine the degree of risk of MS. Those with lesions consistent with MS (two or more) are at high risk, currently estimated at 88% within 20 years. Those with a normal brain on MRI have a much lower risk, 19% at 20 years. 2, 4 Some experts advocate prophylactic treatment with disease-modifying therapy for highrisk patients. 19 The prognosis for MS attacks may be much better than for NMO attacks, and some would argue that it would be worth waiting to determine if further disease activity occurs, given the highly variable and often favorable prognosis of MS. 20 This is a major point of controversy regarding management of CIS. Other predictors of recurrence include CSF OCBs. 21, 22 MRI remains the single most potent predictor, although it is subject to problems of specificity of MRI-identified brain lesions for demyelinating disease.
Acute Infectious Myelopathies
Viral, bacterial, fungal, and parasitic agents can cause acute myelitis (Fig. 4) . Patients are systemically ill with fever and meningismus. Prominent CSF inflammation (pleocytosis, often neutrophilic and raised protein concentration) must prompt investigation for a causative agent, especially a treatable one. This is in contrast to parainfectious or idiopathic inflammatory myelitis where patients have recovered from a recent infection, usually viral. Table 5 lists clinical clues to an infectious cause, Table 6 lists the infectious agents, and Table 7 provides diagnostic studies. However, in most cases of acute viral myelitis, a specific viral cause is never determined. 23 
Myelopathies Associated with Other Inflammatory Disorders
Connective tissue disorders and granulomatous disorders may present with acute or subacute myelitis. SLE, Sjögren's syndrome, scleroderma, mixed connective tissue disorder (MCTD), Behçet's disease, and sarcoidosis ( Fig. 5 ) have all been associated with myelitis. [24] [25] [26] However, it is rare for myelitis to be the presenting symptom. Almost invariably, classical systemic features, brain, or meningeal involvement, at least on MRI, will be present before development of myelitis. In general, established criteria for these disorders should be satisfied before the myelitis is attributed to these disorders. CSF is usually inflammatory, and MRI of the spinal cord may show enhancing lesions. The significance of an autoantibody (e.g., antinuclear antibody [ANA]) in isolation without consistent systemic clinical features is suspect. Table 8 lists the conditions that could cause acute inflammatory myelopathy and criteria needed to diagnose them. Recent evidence suggests that the presence of autoantibodies in patients with acute myelitis may suggest that the myelitis is an NMO spectrum disorder. This is because NMO-IgG is present in approximately half such cases, whereas it is absent in patients with connective tissue diseases, such as SLE and Sjögren's syndrome, who do not have a history of myelitis or optic neuritis.
Vascular Disorders
The arterial supply of the spinal cord consists of a single anterior spinal artery and two posterior spinal arteries (that course vertically over the surface of the cord) and their penetrating branches. 27 Acute vascular occlusion can lead to spinal cord infarction mimicking myelitis (Fig. 6) . Arterial occlusions are rare and develop acutely over minutes. However, arteriovenous fistulas (AVFs) usually progress slowly due to gradual ischemia resulting from venous congestion. Sudden decompensation of myelopathy caused by AVFs or bleeding into vascular malformations may also mimic myelitis (Fig. 7) . CSF is usually normal, although spinal AVF can lead to elevated CSF protein concentration without pleocytosis. Causes of acute vascular myelopathies and diagnostic clues are listed in Table 9 .
Neoplasia and Myelopathy
Intramedullary metastatic disease and intradural extramedullary compressive tumors (neurofibromas and meningiomas) are common causes of acute or acuteon-chronic myelopathy. Primary intramedullary cord tumors (ependymomas, astrocytomas, hemangioblastomas) or metastatic intramedullary tumors usually present over weeks. This is not a difficult diagnosis when there is an enhancing heterogenous lesion on MRI, especially with known systemic cancer. However, certain situations may cause diagnostic dilemmas.
ACUTE PRESENTATIONS OF SPINAL TUMORS
Hemorrhage or infarction of tumors resulting in acute swelling can mimic myelitis. Intramedullary cord lymphomas may respond symptomatically and radiologically to corticosteroids, which can further confuse the diagnosis. If serial imaging, CSF studies, and a search for a primary neoplasm are inconclusive, cord biopsy may be necessary. OCBs in CSF may be seen with tumors, but persistence of the bands is unusual. 28 Persisting gadolinium enhancement months after treatment of an acute myelitis should alert physicians to a potential neoplasm. 28 
RADIATION-ASSOCIATED MYELOPATHY
Radiation-induced myelopathies are usually slowly progressive but may occur up to 15 years after the end of radiation treatment, which may obscure the role of radiation therapy in causing the myelopathy. Early in the course, cord swelling or enhancement may be seen, but later atrophy may be the only finding. 29 Myokymia may be evident on electromyography (EMG) in affected muscles. MRI may show cord lesions indistinguishable from inflammatory lesions, but the simultaneous involvement of the adjacent vertebrae (usually hyperintense on T2-weighted scans) in the same field of radiation is an important clue to the etiology (Fig. 8) .
Paraneoplastic Disorders and Myelopathy
When paraneoplastic antibodies are identified in neurological syndromes, they usually predict an underlying cancer and not necessarily a specific neurological syndrome. 30 Several paraneoplastic antibodies are associated with subacute myelopathies, and a search for such antibodies and an underlying malignancy is warranted if other etiologies for the myelopathy are not apparent (Table 10 ). Autoimmunity to CRMP5 may lead to myelopathy and optic neuropathy that may mimic NMO, 31 and when present, should spur a search for an underlying small cell lung carcinoma. Amphiphysin-specific antibodies raise the possibility of breast cancer. Detection of a longitudinally extensive tractspecific lesion, usually symmetrically involving both sides of the cord, may occur with diverse cancers. We have recently recognized this finding, particularly when accompanied by gadolinium enhancement, as a specific radiological sign of a paraneoplastic myelopathy (Fig. 9) . Some paraneoplastic conditions may mimic a myelopathy, although they are more likely ''neurochemical'' (e.g., GAD65 autoimmunity and stiff man syndrome-associated spasms may mimic spasticity; amphiphysin and rigidity/myoclonus may mimic spasticity). [32] [33] [34] [35] Myelopathy with Normal Magnetic Resonance Imaging Occasionally, the MRI is normal in the setting of an acute myelopathy. There are several potential explanations. First, the syndrome may not be a myelopathy. Guillain-Barré syndrome may be mistaken as myelitis, especially considering the abnormal CSF protein concentration and ascending symptoms that may mimic those seen in myelitis. Enhancing nerve roots on MRI may be a clue to an inflammatory radiculopathy (Fig. 10) . It is uncommon to find an acellular CSF in acute inflammatory myelitis. Second, it may not be an acute problem. It is well known that trivial trauma or environmental or physiological stressors like viral illnesses may decompensate a longstanding myelopathy, making it symptomatic to the patient. Friedreich's ataxia, motor neuron disease, vitamin B 12 or copper deficiency myelopathy, hereditary spastic paraparesis, human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV-1)-myelopathy, and adrenomyeloneuropathy may all have such ''pseudo-acute'' presentations. MRI scans are more often normal than not in these disorders.
Imaging performed during the convalescent phase may miss a cord lesion. The quality of the images may Low-strength magnet (0.5 T)
Were the images taken too early or too late in time and therefore ''missed'' the lesion (i.e., before it appeared or after it resolved)?
Long lesions of NMO may appear patchy or short, and hence nondiagnostic, if imaging is performed in the convalescent phase
Is the lesion too small to be seen on MRI?
Is the weakness not organic (''functional'')?
ALS, amyotrophic lateral sclerosis; HTLV-1, human T-lymphotropic virus 1; HIV, human immunodeficiency virus; NMO, neuromyelitis optica.
have been suboptimal, especially in terms of resolution of an intramedullary lesion. Repeat imaging using sedation, if necessary, to prevent movement-related artifact may be needed if suspicion of myelopathy is high. Table 11 lists the various other possibilities for myelopathy with normal MRI.
CONCLUSION
Although inflammatory demyelinating etiologies account for a high proportion of acute myelopathies, other diagnoses need to be excluded. Once a demyelinating pathology is deemed likely, the chance of recurrence should be considered and, if appropriate, preventative treatments should be initiated. The proportion of idiopathic inflammatory myelitis is likely to decline with the increasing availability of newer autoimmune markers, imaging techniques, and microbiological tests capable of defining a specific etiology for an acute myelopathy.
